You Can’t Delegate Accountability to AI: Jose Caraballo-Oramas

In this episode of Out of the Lab, we tackle the intersection of cutting-edge technology and strict biopharma regulation. We are joined by Jose Caraballo-Oramas (Founder & Principal Advisor, JCO Global Advisory LLC, former Vice President of Global Compliance, Quality Systems & Quality Engineering at Kite Pharma), to discuss the real-world boundaries of AI in GxP environments.

Jose breaks down a crucial reality check for life science innovators: while AI can analyze millions of data points, it cannot legally or operationally hold accountability. He shares insight into why critical decision-making nodes, like batch product release must remain strictly human-driven.

In this episode, we cover:

• The Performance Review Rule: Why the FDA inspects people, not algorithms.

• Peripheral vs. Core GMP: How to safely deploy AI in support workflows like maintenance schedules and document sorting to build regulatory trust.

• Computer Software Assurance (CSA): Utilizing modern FDA guidelines to replace redundant "checkbox" testing with risk-based critical thinking.

  Show notes:

• 00:00 — Introduction & Welcome

• 00:31 — The FDA’s "Hot-Off-the-Press" AI Warning Letter

• 01:45 — The "Cringiest" AI Regulatory Citation

• 04:58 — The Golden Rule of GMP: You Can't Delegate Accountability

• 06:01 — AI as an Operational Aid vs. Decision Maker

• 07:25 — Hospital Procurement & The 2% Error Margin

• 10:24 — Validated Applications: Inspection & Automation

• 11:58 — Unpacking the FDA's Computer Software Assurance (CSA) Guidelines

• 12:57 — Shifting from Checkbox Validation to Critical Thinking

• 14:26 — The True Application of CSA

• 15:58 — Timeline Compression: The Strategic Benefits for Biotech

• 17:56 — Debunking the Myth: CSA is Not "Less Documentation"

• 18:44 — The Bedside Impact: When Does Validation Help the Patient?

• 22:03 — Episode Outro & Wrap-Up